Reta-Cagri 5mg/5mg
Pre-blended stack for comparative research work.
Pre-blended Cagrilintide + Retatrutide research stack — amylin analog combined with a triple-agonist (GLP-1/GIP/glucagon) compound. One of the most advanced incretin-combination research designs available.
Proposed mechanism
Retatrutide activates GLP-1, GIP, and glucagon receptors; cagrilintide adds amylin/calcitonin receptor activation. Four-receptor coverage across incretin and satiety signaling.
Research highlights
- Quad-pathway metabolic research coverage
- Co-lyophilized cagrilintide + retatrutide
- Weekly-dosing research profile
- Frontier combination in peptide-metabolic research
Research protocol notes
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and comparative studies
Pre-stacked — rarely combined further.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
What ratios are available?
5mg + 5mg and 10mg formats — see product specs for exact composition.
How does this compare to Cagri-Sema?
Cagri-Sema pairs cagrilintide with the GLP-1-only agonist semaglutide. Cagri-Reta uses the triple-agonist retatrutide instead — broader receptor coverage.
Is this the most potent metabolic research stack?
By receptor-coverage breadth, yes — it spans GLP-1, GIP, glucagon, and amylin pathways.
Weekly dosing?
Yes — both components support weekly research protocols.
